BioCrossroads

Lumavate, LLC operates a cloud-based software platform that empowers manufacturers to enhance customer experiences through mobile engagement. The platform allows product manufacturers and brands to transform their labels into interactive channels, providing end-users with essential information for product repairs, authentic parts sourcing, and easy access to services and technicians. Catering to a diverse range of industries, Lumavate serves clients in sectors such as infrastructure, outdoor activities, and industrial markets, including healthcare equipment and HVAC systems. The company's enterprise platform is designed for building progressive web apps (PWAs) at scale, enabling companies to deliver personalized mobile experiences that drive user engagement and adoption throughout the customer journey. Founded in 2015 and based in Carmel, Indiana, Lumavate was previously known as LabelNexus, LLC before rebranding in July 2015.

Novosteo Inc., founded in 2017 and located in West Lafayette, Indiana, focuses on developing and manufacturing innovative drugs aimed at treating bone injuries and diseases. The company addresses significant health issues related to bone fractures, including morbidity, mortality, and reduced mobility and productivity. Its scientific co-founders from Purdue University have pioneered a proprietary chemistry approach that targets bone regeneration. Novosteo's drug discovery platform features a range of fracture-targeted therapeutics designed to deliver healing agents directly to fracture sites, enhancing the healing process and alleviating the debilitating effects associated with bone injuries. Through its novel biologics, Novosteo aims to improve patient outcomes and quality of life.

MBX Biosciences, Inc. is a biotechnology company based in Carmel, Indiana, specializing in the development of therapeutics for rare endocrine disorders. Established in 2018, the company focuses on creating peptides aimed at treating genetic diseases that affect glandular hormones, which play a crucial role in the body’s chemical messaging system. By targeting conditions with inadequate treatment options, MBX Biosciences is dedicated to discovering, developing, and commercializing innovative endocrine therapeutics.

Sexton Biotechnologies is a biotechnology company founded in 2019 and based in Indianapolis, Indiana. The company specializes in developing and selling bioproduction tools for cell and gene therapy (CGT), focusing on tools and media that facilitate flexible automation and scaling of cell manufacturing processes. This innovation aims to enhance positive clinical outcomes in CGT applications. Recently, Sexton Biotechnologies raised $5 million in growth capital, marking its emergence as an independent entity following incubation by Cook Regentec. The company plans to leverage this funding to advance ongoing research and product development while expanding the commercialization of its portfolio, which includes container closure and media supplementation tools designed specifically for CGT bioproduction.

Lumavate, LLC operates a cloud-based software platform that empowers manufacturers to enhance customer experiences through mobile engagement. The platform allows product manufacturers and brands to transform their labels into interactive channels, providing end-users with essential information for product repairs, authentic parts sourcing, and easy access to services and technicians. Catering to a diverse range of industries, Lumavate serves clients in sectors such as infrastructure, outdoor activities, and industrial markets, including healthcare equipment and HVAC systems. The company's enterprise platform is designed for building progressive web apps (PWAs) at scale, enabling companies to deliver personalized mobile experiences that drive user engagement and adoption throughout the customer journey. Founded in 2015 and based in Carmel, Indiana, Lumavate was previously known as LabelNexus, LLC before rebranding in July 2015.

SpeechVive Inc. is a medical technology company based in Lafayette, Indiana, founded in 2011. It focuses on developing an innovative wearable device aimed at improving communication for individuals with Parkinson's disease. The device enhances speech volume and clarity by reducing background noise, thereby facilitating better hearing and communication for patients. By addressing the specific challenges faced by those with Parkinson's, SpeechVive aims to empower users to lead more normal lives through improved verbal communication.

Assembly Pharmaceuticals is a virology-focused biopharmaceutical company with a discovery platform and programs based on proprietary Core Protein Allosteric Modulators (CpAMs) for the treatment of viral infections, starting with hepatitis B (HBV). CpAMs can alter the activities of the HBV core protein, a unique viral protein with no human analogue that is involved in multiple stages of the HBV life cycle. In contrast to current therapies that only suppress HBV, Assembly Pharmaceutical’s CpAMs may have curative potential by eliminating the viral reservoir in infected individuals. Hepatitis B infection has a worldwide prevalence of over 350 million and more than 600,000 people die every year from complications associated with chronic HBV. Assembly has operations in Indiana and San Francisco.

Apexian Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in Indianapolis, Indiana, focused on developing innovative compounds for cancer treatment. The company's lead product, APX3330, is an oral anticancer agent that targets the APE1/Ref-1 redox protein, a molecule implicated in various cancers, including those affecting the colon, lung, breast, and pancreas. Founded in 2007, Apexian Pharmaceuticals emerged from research conducted by Dr. Mark R. Kelley, which provided insights into the biological mechanisms associated with APE1/Ref-1. In addition to its work in oncology, the company is also exploring treatments for other conditions, such as bladder cancer, sarcomas, age-related macular degeneration, and inflammatory bowel disease. By focusing on the discovery and development of novel pharmaceuticals, Apexian aims to improve patient outcomes through targeted therapies.

Diagnotes, Inc. is a digital healthcare company based in Indianapolis, Indiana, that specializes in enhancing communication and collaboration within the healthcare industry. Established in 2010, the company offers a clinical communication platform designed to facilitate secure messaging, provider scheduling, patient data management, and documentation of discussions. This platform is tailored to the needs of various stakeholders, including patients, physicians, care teams, hospitals, health systems, and physician practices, enabling them to efficiently manage all patient-related communications. Diagnotes' applications are intuitive and easily adopted, serving a diverse clientele that includes large health systems, community hospitals, long-term care facilities, and behavioral health organizations. The platform supports a range of functionalities, from simple messaging to telehealth consultations, ensuring effective communication among healthcare professionals and their patients on a unified, cloud-based system.

Bioscience Vaccines, Inc. is a life sciences company based in West Lafayette, Indiana, specializing in the development of vaccine adjuvants and companion products aimed at preventing infectious diseases. The company is known for its proprietary technology, the Matrix Immune Modulator, which has its origins in the research conducted by Dr. Mark Suckow at the University of Notre Dame and builds upon discoveries made at Purdue University. This innovative technology has the potential to enhance existing FDA-approved vaccines for both human and animal diseases, and the company is also exploring immunotherapeutic treatments for cancer using tissue vaccines.

ImmuneWorks, Inc. is a biotechnology company based in Indianapolis, Indiana, founded in 2006. The company focuses on developing immune tolerance therapies aimed at treating idiopathic pulmonary fibrosis and other fibrotic lung diseases. ImmuneWorks is grounded in the discovery that antigen-specific autoimmunity contributes to the disease in more than half of idiopathic pulmonary fibrosis cases. By utilizing advanced biotechnological procedures, the company seeks to create safe and effective treatments for patients suffering from serious autoimmune diseases affecting the lungs, ultimately aiming to enhance their quality of life.

CS-Keys is a private, Indianapolis-based biotechnology company focused on the discovery and development of 3rd generation cancer-associated biomarkers using proteomics. These biomarkers may be used to create products to enhance the diagnosis and treatment of patients with cancer.